Biocytogen Pharmaceuticals Achieves Key Milestones in Patent and Drug Development
Biocytogen Pharmaceuticals Beijing Co., Ltd., a prominent player in China’s healthcare sector, has recently made significant strides in both patent acquisition and drug development. Listed on the Hong Kong Stock Exchange under the ticker 02315, the company has been actively enhancing its global intellectual property portfolio and advancing its drug candidates.
Patent Acquisition in Japan
On June 6, 2025, Biocytogen announced that its RenMab fully human antibody mouse platform had been granted an invention patent by the Japan Patent Office (JPO). This achievement is a crucial step in bolstering the global intellectual property portfolio of the RenMice fully human antibody platform family. The patent underscores Biocytogen’s commitment to its comprehensive global patent strategy and highlights the international recognition of its proprietary technologies. The RenMab mice are integral to Biocytogen’s independently developed RenMice fully human antibody discovery platform, which is known for its innovative Size-Unlimited and Precise Chromosome Engineering technology.
IND Approval for Anti-IGF-1R Antibody NTB003
In another significant development, Biocytogen, in collaboration with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., announced that their co-developed injectable drug candidate, NTB003 (formerly BCG009), has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA). The approval is for the indication of Thyroid Eye Disease (TED). NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody. The antibody’s discovery and optimization were spearheaded by Biocytogen using its proprietary RenMab platform, while Nanjing Chia Tai Tianqing handled the chemistry, manufacturing, and controls (CMC) process development, as well as GLP-compliant toxicology studies.
Company Overview
Biocytogen Pharmaceuticals Beijing Co., Ltd. operates as a biopharmaceutical and preclinical research services company. It specializes in producing biological agents such as monoclonal antibodies and recombinant humanized antibodies. The company is actively involved in drug development and therapeutic antibody discovery and development. As of June 4, 2025, Biocytogen’s close price was 17.68 HKD, with a market capitalization of 5.44 billion HKD. The company’s price-to-earnings ratio stands at 159.54, reflecting its growth potential and market expectations.
These recent developments highlight Biocytogen’s ongoing efforts to strengthen its position in the biopharmaceutical industry through strategic patent acquisitions and successful drug development initiatives. For more information, visit their website at www.biocytogen.com.cn .